The Business Research Company’s Lung Cancer Drugs Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Lung Cancer Drugs Global Market Report 2023 evaluates lung cancer drugs market size, growth rate, drivers, trends, and major companies.
The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Free Sample Of The Report (Includes Graphs And Tables):
The global lung cancer drugs market size will grow from $32.67 billion in 2022 to $36.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global lung cancer drugs market size is expected to grow to $54.43 billion in 2027 at a CAGR of 10.5%.
The lung cancer drugs market segments in the report are:
1) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)
2) By End User: Hospitals, Clinics, Other End-Users
3) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs
Get More Information On The Lung Cancer Drugs Market Report:
The table of contents in TBRC’s lung cancer drugs market report includes:
Top 5 Major Key Players Are:
List Of Tables:
Table 1: Global Historic Market Growth, 2017-2022, $ Billion
Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Table 3: Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 4: Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 5: Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 65: Bristol-Myers Squibb Company Financial Performance
Table 66: Merck & Co. Financial Performance
Table 67: F. Hoffmann-La Roche Ltd Financial Performance
Table 68: Novartis AG Financial Performance
Table 69: Pfizer Inc. Financial Performance
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model